In last trading session, Outlook Therapeutics Inc (NASDAQ:OTLK) saw 0.35 million shares changing hands with its beta currently measuring 0.38. Company’s recent per share price level of $1.57 trading at $0.09 or 6.08% at ring of the bell on the day assigns it a market valuation of $50.27M. That closing price of OTLK’s stock is at a discount of -718.47% from its 52-week high price of $12.85 and is indicating a premium of 44.59% from its 52-week low price of $0.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.32 million shares which gives us an average trading volume of 817.79K if we extend that period to 3-months.

For Outlook Therapeutics Inc (OTLK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.55 in the current quarter.

Outlook Therapeutics Inc (NASDAQ:OTLK) trade information

Outlook Therapeutics Inc’s shares saw a change of -16.93% in year-to-date performance and have moved 5.37% in past 5-day. Outlook Therapeutics Inc (NASDAQ:OTLK) showed a performance of -9.77% in past 30-days. Number of shares sold short was 3.5 million shares which calculate 5.47 days to cover the short interests.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 702.6k for the same. And 5 analysts are in estimates of company making revenue of 2.26M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.45% during past 5 years.

Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders

Insiders are in possession of 37.11% of company’s total shares while institution are holding 16.93 percent of that, with stock having share float percentage of 26.91%. Investors also watch the number of corporate investors in a company very closely, which is 16.93% institutions for Outlook Therapeutics Inc that are currently holding shares of the company. ROSALIND ADVISORS, INC. is the top institutional holder at OTLK for having 0.45 million shares of worth $3.32 million. And as of 2024-06-30, it was holding 3.1534 of the company’s outstanding shares.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 442.51 shares of worth $0.69 million or 1.38% of the total outstanding shares. The later fund manager was in possession of 387.53 shares on Dec 31, 2024 , making its stake of worth around $0.61 million in the company or a holder of 1.21% of company’s stock.